ArticleCancer cell international2009
Therapeutic implications of osteoprotegerin.
Article in Cancer cell international, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.
- Effects of Resveratrol, Curcumin and Quercetin Supplementation on Bone Metabolism-A Systematic Review.Nutrients · 2022Pooled it
- New Perspectives of Therapies in Osteogenesis Imperfecta-A Literature Review.Journal of clinical medicine · 2024Review
- "Lessons from Rare Forms of Osteoarthritis".Calcified tissue international · 2021Review
- An Iranian Woman with Parathyroid Adenoma and Palpable Breast Masses Due to Bilateral and Asymmetric Calcifications.Indian journal of surgical oncology · 2020Article
- Resveratrol promotes osteoblastic differentiation in a rat model of postmenopausal osteoporosis by regulating autophagy.Nutrition & metabolism · 2020Article
- Local application of osteoprotegerin-chitosan gel in critical-sized defects in a rabbit model.PeerJ · 2017Article
- Textural entropy as a potential feature for quantitative assessment of jaw bone healing process.Archives of medical science : AMS · 2015Article
- Adenovirus-mediated transfer of VEGF into marrow stromal cells combined with PLGA/TCP scaffold increases vascularization and promotes bone repair in vivo.Archives of medical science : AMS · 2014Article
- Understanding and targeting osteoclastic activity in prostate cancer bone metastases.Current molecular medicine · 2013Review
- Immediately transcripted genes in various hepatic ischemia models.Journal of the Korean Surgical Society · 2012Article
- Potential Markers in Cardiac Hypertrophy?EJIFCC · 2012Article
- Age-related BMAL1 change affects mouse bone marrow stromal cell proliferation and osteo-differentiation potential.Archives of medical science : AMS · 2012Article
- Pathogenesis of Metastatic Calcification and Acute Pancreatitis in Adult T-Cell Leukemia under Hypercalcemic State.Leukemia research and treatment · 2012Article
- Endocrine and metabolic emergencies: hypercalcaemia.Therapeutic advances in endocrinology and metabolism · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoprotegerin (OPG), a member of the tumor necrosis factor (TNF) receptor superfamily, contributes determinatively to the bone remodeling as well as to the pathogenetic mechanism of bone malignancies and disorders of mineral metabolism. There is additional evidence that OPG can promote cell survival by inhibiting TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis. A number of recent in vitro, in vivo and clinical studies have defined the role of the RANK/RANKL/OPG pathway in skeletal and vascular diseases. These works were the milestone of the deep understanding of the mechanism of OPG. This review provides an overview of the potential innovative therapeutic strategies of OPG in metastatic breast and prostate carcinoma, multiple myeloma, postmenopausal osteoporosis, glucocorticoid-induced osteoporosis and rheumatoid arthritis. Special reference is given to the increasing evidence that RANKL and OPG may link the skeletal with the vascular system.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.